India Drug Makers Struggle To Follow Lupin Into Japan's Generics Market
This article was originally published in PharmAsia News
Lupin may have made it, but no other India drug maker has been able to set up business in Japan, the second-largest pharmaceutical market in the world and considered to be worth $90 billion.
You may also be interested in...
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.
A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.